ANI Pharmaceuticals Inc (NASDAQ:ANIP) Director Tracy Marshbanks sold 15,391 shares of ANI Pharmaceuticals stock in a transaction that occurred on Thursday, March 8th. The shares were sold at an average price of $63.08, for a total transaction of $970,864.28. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Tracy Marshbanks also recently made the following trade(s):
- On Monday, March 12th, Tracy Marshbanks sold 64,221 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $63.03, for a total transaction of $4,047,849.63.
ANI Pharmaceuticals Inc (NASDAQ:ANIP) traded down $0.13 during midday trading on Monday, reaching $62.75. 103,252 shares of the company’s stock traded hands, compared to its average volume of 164,378. The company has a quick ratio of 2.39, a current ratio of 3.36 and a debt-to-equity ratio of 1.13. ANI Pharmaceuticals Inc has a fifty-two week low of $42.23 and a fifty-two week high of $74.70. The stock has a market capitalization of $730.60, a price-to-earnings ratio of 59.20 and a beta of 2.75.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ANIP. Dimensional Fund Advisors LP grew its holdings in ANI Pharmaceuticals by 91.1% in the second quarter. Dimensional Fund Advisors LP now owns 339,268 shares of the specialty pharmaceutical company’s stock worth $15,878,000 after purchasing an additional 161,743 shares during the last quarter. Cortina Asset Management LLC purchased a new position in ANI Pharmaceuticals in the fourth quarter worth $6,091,000. JPMorgan Chase & Co. grew its holdings in ANI Pharmaceuticals by 868.2% in the third quarter. JPMorgan Chase & Co. now owns 104,829 shares of the specialty pharmaceutical company’s stock worth $5,404,000 after purchasing an additional 94,002 shares during the last quarter. Triarii Capital Management LP purchased a new position in ANI Pharmaceuticals in the fourth quarter worth $3,283,000. Finally, Nexthera Capital LP purchased a new position in ANI Pharmaceuticals in the fourth quarter worth $2,701,000. 55.95% of the stock is currently owned by institutional investors and hedge funds.
A number of equities analysts recently commented on ANIP shares. BidaskClub downgraded shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, December 21st. Canaccord Genuity set a $75.00 price objective on shares of ANI Pharmaceuticals and gave the stock a “buy” rating in a research note on Saturday, December 9th. ValuEngine raised shares of ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, November 25th. Zacks Investment Research downgraded shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, January 2nd. Finally, TheStreet raised shares of ANI Pharmaceuticals from a “c+” rating to a “b” rating in a research note on Thursday, November 16th. One analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company’s stock. ANI Pharmaceuticals has an average rating of “Hold” and an average price target of $72.25.
TRADEMARK VIOLATION NOTICE: “Tracy Marshbanks Sells 15,391 Shares of ANI Pharmaceuticals Inc (ANIP) Stock” was posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The correct version of this story can be read at https://www.americanbankingnews.com/2018/03/12/tracy-marshbanks-sells-15391-shares-of-ani-pharmaceuticals-inc-anip-stock.html.
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.